Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 4 studies | 20% ± 4% | |
hematopoietic precursor cell | 3 studies | 18% ± 3% | |
transit amplifying cell | 3 studies | 41% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1316.03 | 1444 / 1445 | 100% | 37.25 | 183 / 183 |
lung | 100% | 1243.81 | 578 / 578 | 100% | 27.23 | 1153 / 1155 |
intestine | 100% | 1191.93 | 966 / 966 | 100% | 29.10 | 526 / 527 |
bladder | 100% | 1200.10 | 21 / 21 | 100% | 26.53 | 502 / 504 |
breast | 100% | 1306.55 | 459 / 459 | 99% | 26.09 | 1111 / 1118 |
skin | 100% | 2486.41 | 1809 / 1809 | 99% | 27.74 | 469 / 472 |
stomach | 100% | 917.70 | 359 / 359 | 99% | 28.10 | 284 / 286 |
uterus | 100% | 1281.82 | 170 / 170 | 99% | 31.96 | 455 / 459 |
pancreas | 100% | 968.33 | 328 / 328 | 99% | 15.98 | 176 / 178 |
thymus | 100% | 1323.79 | 653 / 653 | 98% | 16.15 | 593 / 605 |
ovary | 100% | 1237.03 | 180 / 180 | 98% | 17.63 | 420 / 430 |
kidney | 100% | 1044.36 | 89 / 89 | 94% | 13.46 | 847 / 901 |
brain | 93% | 587.45 | 2454 / 2642 | 97% | 13.99 | 682 / 705 |
prostate | 100% | 1179.82 | 245 / 245 | 88% | 10.28 | 444 / 502 |
adrenal gland | 100% | 875.43 | 258 / 258 | 85% | 10.15 | 195 / 230 |
liver | 98% | 536.78 | 222 / 226 | 59% | 6.79 | 239 / 406 |
adipose | 100% | 1185.69 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 981.93 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 31.67 | 29 / 29 |
spleen | 100% | 1698.47 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 36.21 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.53 | 1 / 1 |
peripheral blood | 94% | 1760.46 | 870 / 929 | 0% | 0 | 0 / 0 |
heart | 92% | 454.84 | 794 / 861 | 0% | 0 | 0 / 0 |
muscle | 86% | 444.24 | 694 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 86% | 10.04 | 69 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0036297 | Biological process | interstrand cross-link repair |
GO_0010212 | Biological process | response to ionizing radiation |
GO_0006974 | Biological process | DNA damage response |
GO_0000724 | Biological process | double-strand break repair via homologous recombination |
GO_0031297 | Biological process | replication fork processing |
GO_0031571 | Biological process | mitotic G1 DNA damage checkpoint signaling |
GO_2000001 | Biological process | regulation of DNA damage checkpoint |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090734 | Cellular component | site of DNA damage |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0035861 | Cellular component | site of double-strand break |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0097371 | Molecular function | MDM2/MDM4 family protein binding |
GO_0002039 | Molecular function | p53 binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | RFWD3 |
Protein name | Ring finger and WD repeat domain 3 E3 ubiquitin-protein ligase RFWD3 (EC 2.3.2.27) (RING finger and WD repeat domain-containing protein 3) (RING finger protein 201) |
Synonyms | RNF201 |
Description | FUNCTION: E3 ubiquitin-protein ligase required for the repair of DNA interstrand cross-links (ICL) in response to DNA damage . Plays a key role in RPA-mediated DNA damage signaling and repair . Acts by mediating ubiquitination of the RPA complex (RPA1, RPA2 and RPA3 subunits) and RAD51 at stalled replication forks, leading to remove them from DNA damage sites and promote homologous recombination . Also mediates the ubiquitination of p53/TP53 in the late response to DNA damage, and acts as a positive regulator of p53/TP53 stability, thereby regulating the G1/S DNA damage checkpoint . May act by catalyzing the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome . In response to ionizing radiation, interacts with MDM2 and enhances p53/TP53 ubiquitination, possibly by restricting MDM2 from extending polyubiquitin chains on ubiquitinated p53/TP53 . Required to translesion DNA synthesis across DNA-protein cross-link adducts by catalyzing ubiquitination of proteins on single-stranded DNA (ssDNA) . . |
Accessions | ENST00000361070.9 Q6PCD5 ENST00000572337.5 ENST00000575113.1 ENST00000571750.5 I3L284 I3L299 ENST00000576652.1 I3L2T2 ENST00000572990.5 I3L4I5 |